AHA In Brief
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific TAXUS I: Angiographic analysis at six-month follow-up of 61 patients demonstrated zero edge effect at the proximal and distal edges in both the treatment and control arm of the paclitaxel-coated Nirx stent trial. Intravascular ultrasound (IVUS) analysis showed "significant improvements" in neointimal volume, percent neointimal volume index and minimum lumen area in the treatment group, the firm says. The newly reported data "expand on the impressive results reported earlier, and they reduce the concern that an edge effect may be the price we pay for reducing in-stent restenosis," commented Eberhard Grube, MD, Seigburg Heart Center, Siegburg, Germany...